Celldex Therapeutics, Inc.
CLDX
$32.49
$0.491.53%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 3.24% | -21.29% | -18.45% | -5.21% | -14.24% |
| Total Depreciation and Amortization | 4.66% | -0.97% | -5.61% | 0.69% | 5.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.63% | 3.06% | 3.78% | 6.41% | 9.84% |
| Change in Net Operating Assets | -49.06% | -12.95% | 132.46% | 149.64% | -215.18% |
| Cash from Operations | -2.58% | -31.49% | -10.51% | 19.07% | -67.42% |
| Capital Expenditure | -27.95% | -191.14% | 39.56% | -174.72% | 64.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 30.07% | -7.47% | 21.17% | 17.04% | 74.23% |
| Cash from Investing | 30.12% | -8.91% | 22.06% | 16.07% | 78.61% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -75.76% | 74.29% | 1,128.57% | -68.81% | -47.67% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -75.76% | 74.29% | 1,128.57% | -68.81% | -47.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 195.70% | -155.15% | 119.92% | 152.66% | -39.50% |